Sopan Pharmaceuticals IPO Approval Granted
2nd March 2026, Kathmandu
The capital market of the Federal Democratic Republic of Nepal has reached a transformative milestone as the Sopan Pharmaceuticals IPO Approval has officially been granted by the Securities Board of Nepal (SEBON). On March 1, 2026 (Falgun 17, 2082), the regulatory body cleared the company to move forward with its Initial Public Offering, making it the second pharmaceutical manufacturing entity to enter the Nepal Stock Exchange (NEPSE). This approval is a significant breakthrough for the primary market, which has historically been dominated by banks and hydropower companies. By issuing 42.9 lakh ordinary shares (4,290,000 units) at a face value of 100 rupees per share, Sopan Pharmaceuticals is set to mobilize 42.90 crore rupees from the general public. In the year 2082, as Nepal seeks to reduce its heavy reliance on imported medicines, this IPO represents a strategic shift toward self sufficiency in the healthcare sector and offers a unique diversification opportunity for retail and institutional investors alike.
Sopan Pharmaceuticals IPO Approval
The leadership of Sopan Pharmaceuticals Limited brings together a diverse group of professionals and corporate entities. Under the chairmanship of Dr Anil Pokharel and the executive direction of CEO Suman Neupane, the board includes experienced members such as Bhim Lal Poudyal, Kriti Kumari Mahato, Anish Shah, and Ang Dorje Lama. A cornerstone of the company’s financial stability is the 49 percent ownership stake held by Sopan Multiple, which provides strong institutional backing within the group structure. This governance framework is particularly important in the pharmaceutical industry, where strict adherence to quality control and international manufacturing standards is required for long term sustainability and regulatory compliance.
The operational journey of Sopan Pharmaceuticals began in 2074 BS with the initiation of physical infrastructure development in Mahalaxmi Municipality Ward No 8, Lalitpur. Spanning over 21 ropani and 9 aana of land, the facility reached full commercial production by 2079 BS after successful pilot scale launches. The industrial complex is divided into two major specialized blocks. The Non Beta Lactam Block, covering over 51,000 square feet, houses the production lines for tablets, capsules, ointments, and liquid formulations. The Cephalosporin Block, spanning over 35,000 square feet, is dedicated to the production of high potency antibiotics in tablet, capsule, and dry syrup forms. This infrastructure is equipped with state of the art technology designed to meet Global Good Manufacturing Practice (GMP) standards, ensuring that the products are competitive with imported alternatives.
The production capacity of Sopan Pharmaceuticals is one of its strongest selling points for potential investors. Even under a conservative single shift operation of 8 hours per day, the facility is capable of producing 84 crore tablets and nearly 10 crore capsules annually. This massive output is complemented by the capacity to produce 3 lakh liters of liquid formulations and 30 lakh bottles of dry powder. If the market demand increases, the current infrastructure allows the company to double its output by simply adding shifts, without requiring significant additional capital expenditure for building expansion. Analysts estimate that with this capacity, the company has the potential to capture approximately 16 percent of the total domestic pharmaceutical market, significantly contributing to the national import substitution strategy.
Advertisement
Adding to the company’s revenue resilience is its vertical diversification into medical oxygen production. Sopan Pharmaceuticals operates a dedicated medical oxygen gas plant within a 10,000 square foot facility with a production capacity of 300 cubic meters per hour. The plant produces a variety of products, from large 7,000 liter industrial cylinders to 10 liter portable oxygen cans designed for household and emergency use. This diversification proved to be a critical asset during the recent public health challenges in Nepal and continues to provide a steady alternative revenue stream that is independent of the traditional medicine market.
The regulatory readiness of the company is further evidenced by its extensive product portfolio. To date, Sopan Pharmaceuticals has successfully developed over 190 formulations and secured 136 drug production licenses. Furthermore, it has already obtained 92 market authorization approvals, allowing it to immediately scale its distribution across the country. This pipeline of approved products reduces the time to market for new treatments and ensures that the company can quickly respond to the changing healthcare needs of the Nepali population. The strategic importance of the Sopan Pharmaceuticals IPO Approval lies in its ability to fund the marketing and distribution of these products, ultimately reducing the country’s trade deficit by providing locally manufactured, high quality alternatives to foreign drugs.
From an investment perspective, the role of NMB Capital Limited as the issue manager ensures that the IPO process will be conducted with transparency and professionalism. NMB Capital will oversee the collection of applications through the C-ASBA system and manage the allotment procedures according to SEBON guidelines. For retail investors, the entry of a pharmaceutical company into the market provides a hedge against the volatility of the hydropower and finance sectors. The pharmaceutical industry is often considered a defensive sector, as the demand for essential medicines remains relatively stable regardless of economic cycles. In the year 2082, this stability is expected to attract significant interest from pension funds, insurance companies, and individual investors seeking long term growth.
In conclusion, the Sopan Pharmaceuticals IPO Approval marks a major turning point for the healthcare and capital markets of the Federal Democratic Republic of Nepal in 2082. By offering 42.9 lakh shares backed by an advanced manufacturing facility and a diverse product range, the company is positioning itself as a leader in the domestic pharmaceutical industry. The guidance of an experienced board and the operational strength of its Mahalaxmi facility provide a solid foundation for future growth. As the subscription window opens, the success of this IPO will be a testament to the public’s confidence in Nepal’s industrial potential. For investors, this is an opportunity to be part of a mission that goes beyond profit, contributing to a healthier and more self reliant nation.
For More: Sopan Pharmaceuticals IPO Approval
